Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Ecolab (ECL) Features In DJSI List For Third Consecutive Year

Published 09/10/2017, 09:58 PM
Updated 07/09/2023, 06:31 AM

For the third year in a row, St. Paul, MN-based Ecolab Inc. (NYSE:ECL) has been selected as a member of the Dow Jones Sustainability Indices (“DJSI”), the global indicator tracking the financial performance of leading sustainability-driven companies. Launched in 1999, DJSI is considered as a benchmark in this area. The index is drawn up by Dow Jones in collaboration with investment management firm Strategic Asset Management (“SAM”).

Ecolab has been selected as a leader in corporate sustainability by the DJSI. The company claims is recognition of its world class services, products, and programs, as well as the successful integration of corporate responsibility and sustainability into overall business practices. This is the third consecutive year the company has been selected and the company’s fourth listing since 2012.

Ecolab is a leading provider of water, hygiene and energy technologies and services that protect people and vital resources. The company's programs and services helps in promoting safe food, maintaining clean environments, optimizing water and energy use and improving operational efficiencies for customers in the food, energy, healthcare, industrial and hospitality markets in more than 170 countries.

Ecolab had an impressive run on the bourse over the last six months, trading above the industry in terms of price performance. A glimpse at the price movement reveals that Ecolab’s shares have gained 5.1% against the industry’s 0.6% decline.

The company’s prospects in the Global Industrial and Global Institutional business segments reflect positivity. In the last reported quarter, sales at both these segments scaled 3%, on a year-over-year basis. Furthermore, Ecolab boasts compelling fundamentals with revenues and adjusted earnings multiplying at a rate of 4.6% and 13.7%, over the last three years.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

However, on the flip side, unfavorable foreign currency and the impact of Venezuelan deconsolidation are expected to hurt earnings in the near term. Also escalating costs and expenses are weighing on its margins. Last month, a comparative study of Ecolab’s forward P/E (forward 12-month basis) multiple reflected that the stock has been quite overvalued.

Zacks Rank & Key Picks

Ecolab currently carries a Zacks Rank #3 (Hold).

A few better-ranked medical stocks are Edwards Lifesciences Corporation (NYSE:EW) , Lantheus Holdings, Inc. (NASDAQ:LNTH) and IDEXX Laboratories, Inc. (NASDAQ:IDXX) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has surged roughly 25.9% over the last six months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has rallied 25.8% over the last six months.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 5.4% over the last six months.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Ecolab Inc. (ECL): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.